High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: A randomised controlled trial

Medicine and Dentistry

• Acromegaly 41%
• Adverse Event 8%
• Chemotherapeutic Agent 8%
• Combination Therapy 33%
• Dose Response 8%
• Drug 8%
• Drug Dose Regimen 8%
• Drug Megadose 66%
• Endocrinology 8%
• Evaluation Study 8%
• Group Frequency 8%
• Group Therapy 8%
• Growth Hormone 16%
• Hemoglobin A1c 8%
• Injection 8%
• Inpatient 25%
• Neoplasm 8%
• Octreotide 41%
• Open-Label Trial 8%
• Patient 41%
• Randomized Controlled Trial 16%
• Serum 8%
• Somatostatin Derivative 58%
• Therapeutic Procedure 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Acromegaly 41%
• Adverse Event 8%
• Drug 8%
• Growth Hormone 16%
• Hemoglobin A1c 8%
• Insulin-Like Growth Factor 1 100%
• Neoplasm 8%
• Octreotide 41%
• Open-Label Trial 8%
• Somatostatin Derivative 58%
• Tolerability 8%